Clinical Trial Update: An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants [Phase 2]

View source ↗

Summary

This open-label Phase 2 study evaluated telaprevir dosed every 12 or 8 hours in combination with one of two pegylated interferons and ribavirin in treatment-nai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)
• Telaprevir (telaprevir)

Snippet

Sponsor: Tibotec BVBA | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2013-05-01